GlassScriptPhysician profile
Traci M Turner
NPI 1780784983
$2,878.86
in general payments reported to CMS, 2019-2025
25 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $127 · 2021: $180 · 2022: $456 · 2023: $428 · 2024: $530 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $789.88 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $427.29 | 2019-2025 | |
| Abiomed | $243.32 | 2024-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.97 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $172.60 | 2019-2024 | Xarelto |
| Pfizer INC. | $143.56 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $134.23 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.19 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.68 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $73.85 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $69.50 | 2021-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $66.39 | 2024 | Arcalyst |
| Novo Nordisk INC | $49.95 | 2021-2022 | |
| Scpharmaceuticals INC. | $45.36 | 2024-2025 | |
| Philips North America LLC | $38.98 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.86 | 2019-2022 | |
| Amarin Pharma, INC. | $26.98 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Resmed Corp | $23.10 | 2020 | |
| Atricure, INC. | $21.48 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Gilead Sciences, INC. | $20.70 | 2019 | |
| Heartflow, INC. | $18.28 | 2023 | Ffrct |
| Alnylam Pharmaceuticals INC. | $13.73 | 2025 | Onpattro |
| Irhythm Technologies, INC. | $13.59 | 2022 | |
| Esperion Therapeutics, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.